HK1052181A1 - 作为双重组胺h1和h3激动剂或拮抗剂的取代咪唑 - Google Patents

作为双重组胺h1和h3激动剂或拮抗剂的取代咪唑 Download PDF

Info

Publication number
HK1052181A1
HK1052181A1 HK03104438.9A HK03104438A HK1052181A1 HK 1052181 A1 HK1052181 A1 HK 1052181A1 HK 03104438 A HK03104438 A HK 03104438A HK 1052181 A1 HK1052181 A1 HK 1052181A1
Authority
HK
Hong Kong
Prior art keywords
agonists
antagonists
substituted imidazoles
dual histamine
methods
Prior art date
Application number
HK03104438.9A
Other languages
English (en)
Chinese (zh)
Inventor
G. Aslanian Robert
B. Rosenblum Stuart
Wa Mutahi Mwangi
Shih Neng-Yang
J. Piwinski John
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of HK1052181A1 publication Critical patent/HK1052181A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK03104438.9A 2000-09-20 2001-09-18 作为双重组胺h1和h3激动剂或拮抗剂的取代咪唑 HK1052181A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23404000P 2000-09-20 2000-09-20
US60/234,040 2000-09-20
PCT/US2001/029064 WO2002024658A2 (en) 2000-09-20 2001-09-18 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists

Publications (1)

Publication Number Publication Date
HK1052181A1 true HK1052181A1 (zh) 2003-09-05

Family

ID=22879630

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03104438.9A HK1052181A1 (zh) 2000-09-20 2001-09-18 作为双重组胺h1和h3激动剂或拮抗剂的取代咪唑

Country Status (14)

Country Link
US (1) US6518287B2 (enExample)
EP (1) EP1318983B1 (enExample)
JP (1) JP2004509870A (enExample)
CN (1) CN1461299A (enExample)
AR (1) AR032895A1 (enExample)
AT (1) ATE411983T1 (enExample)
AU (1) AU2001292723A1 (enExample)
CA (1) CA2421823A1 (enExample)
DE (1) DE60136284D1 (enExample)
ES (1) ES2313985T3 (enExample)
HK (1) HK1052181A1 (enExample)
MX (1) MXPA03002447A (enExample)
MY (1) MY129677A (enExample)
WO (1) WO2002024658A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090527A1 (en) * 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
WO2006028963A2 (en) * 2004-09-03 2006-03-16 Celgene Corporation Substituted heterocyclic compounds and uses thereof
AP2008004537A0 (en) * 2005-12-30 2008-08-31 Ranbaxy Lab Ltd Muscarinic receptor antagonists
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3512084A1 (de) * 1985-04-02 1986-10-09 Ludwig Heumann & Co GmbH, 8500 Nürnberg Guanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2586562B1 (fr) 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
DE3631334A1 (de) * 1986-09-15 1988-03-17 Heumann Pharma Gmbh & Co Neue imidazolylguanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
ES2058651T3 (es) * 1990-03-30 1994-11-01 Heumann Pharma Gmbh & Co Uso derivados de guanidina para la fabricacion de un medicamento con actividad antagonista de npy.
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
ATE128708T1 (de) 1991-12-18 1995-10-15 Schering Corp Imidazolylalkyl- piperazin und -diazepin derivate als histamin h3 agonisten/antagonisten.
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
JPH09505298A (ja) 1993-11-15 1997-05-27 シェーリング コーポレイション Ｈ▲下３▼‐レセプターアンタゴニストとしてのフェニル‐アルキルイミダゾール
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
WO1998058646A1 (en) 1997-06-24 1998-12-30 Novo Nordisk A/S Use of somatostatin agonists and antagonists for treating diseases related to the eye
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
US6211182B1 (en) * 1999-03-08 2001-04-03 Schering Corporation Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms

Also Published As

Publication number Publication date
CN1461299A (zh) 2003-12-10
MXPA03002447A (es) 2003-07-21
AU2001292723A1 (en) 2002-04-02
MY129677A (en) 2007-04-30
US20020103235A1 (en) 2002-08-01
ATE411983T1 (de) 2008-11-15
EP1318983A2 (en) 2003-06-18
JP2004509870A (ja) 2004-04-02
WO2002024658A2 (en) 2002-03-28
ES2313985T3 (es) 2009-03-16
US6518287B2 (en) 2003-02-11
CA2421823A1 (en) 2002-03-28
DE60136284D1 (de) 2008-12-04
EP1318983B1 (en) 2008-10-22
WO2002024658A3 (en) 2002-07-11
AR032895A1 (es) 2003-12-03

Similar Documents

Publication Publication Date Title
WO2004087649A3 (en) Benodiazepine spirohydantoin cgrp receptor antagonists
MXPA02005602A (es) Compuestos de urea que tienen actividad antagonista para el receptor muscarinico.
WO2004082602A3 (en) Carboxamide spirohydantoin cgrp receptor antagonists
MXPA04000707A (es) Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas.
WO2004082605A3 (en) Bicyclic anilide spirohydantoin cgrp receptor antagonists
MXPA02005596A (es) Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
ATE384050T1 (de) Benzazepinderivate als histamin-h3-antagonisten
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
CR9304A (es) Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos
WO2007126935A3 (en) Diazepan orexin receptor antagonists
AP2004002982A0 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
JO2355B1 (en) Hereditary calcitonin polypeptide receptor antagonists
WO2007126934A3 (en) Amidoethylthioether orexin receptor antagonists
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2002072536A8 (en) Urea derivatives having vanilloid receptor (vr1) antagonist activity
MX2009005174A (es) Derivados de 5-sulfanilmetil-[1,2,4]triazol[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
WO2007025069A3 (en) Diazaspirodecane orexin receptor antagonists
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007120284A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2004005262A3 (en) New neuropeptide y y5 receptor antagonists
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
EP1398029A8 (en) NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
WO2005082893A3 (en) Histamine h3 receptor antagonists, preparation and therapeutic uses
AU1092800A (en) N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists
WO2002044141A3 (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists